

8. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riba AL, Thompson MA, Rohrbeck S, Lundergan CF (1999) A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. *J Am Coll Cardiol* 34:1954-1962
9. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell' Infartomiocardico) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. *Lancet* 1:397-402
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17167 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 2:349-360
11. Nakamura F, Minamino T, Higashino Y, Ito H, Fujii K, Fujita T, Nagano M, Higaki J, Ogihara T (1992) Cardiac free wall rupture in acute myocardial infarction: ameliorative effect of coronary reperfusion. *Clin Cardiol* 15:244-250
12. Nakatsuchi Y, Minamino T, Fujii K, Negoro S (1994) Clinicopathological characterization of cardiac free wall rupture in patients with acute myocardial infarction: difference between early and late phase rupture. *Int J Cardiol* 47:33-38
13. Becker RC, Charlesworth A, Wilcox RG, Hampton J, Skene A, Gore JM (1995) Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study. *J Am Coll Cardiol* 25:1063-1068
14. Becker RC, Gore JM, Lambrew C, Weaver WD, Rubison RM, French WJ, Tiefenbrunn AJ, Bowlby LJ, Rogers WJ (1996) A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. *J Am Coll Cardiol* 27:1321-1326
15. Kinn JW, O'Neill WW, Benzuly KH, Jones DE, Grines CL (1997) Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. *Cathet Cardiovasc Diagn* 42:151-157
16. Moreno R, Lopez-Sendon J, Garcia E, Perez de Isla L, Lopez de Sa E, Ortega A, Moreno M, Rubio R, Soriano J, Abeytua M, Garcia-Fernandez MA (2002) Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. *J Am Coll Cardiol* 39:598-603
17. Park WM, Connery CP, Hochman JS, Tilson MD, Anagnostopoulos CE (2000) Successful repair of myocardial free wall rupture after thrombolytic therapy for acute infarction. *Ann Thorac Surg* 70:1345-1349
18. Figueras J, Cortadellas J, Domingo E, Soler-Soler J (2001) Survival following self-limited left ventricular free wall rupture during myocardial infarction. Management differences between patients with or without pseudoaneurysm formation. *Int J Cardiol* 79:103-111
19. Ikeda M, Ohashi H, Tsutsumi Y, Kawai T, Ohnaka M (2002) Endoventricular circular patch plasty with aortic valve replacement for post-infarction cardiac rupture complicated with aortic valve stenosis. *Circ J* 66:974-976

ORIGINAL
RESEARCH

N. Yamada
M. Higashi
R. Otsubo
T. Sakuma
N. Oyama
R. Tanaka
K. Iihara
H. Naritomi
K. Minematsu
H. Naito

Association between Signal Hyperintensity on T1-Weighted MR Imaging of Carotid Plaques and Ipsilateral Ischemic Events

BACKGROUND AND PURPOSE: To investigate associations between cerebral ischemic events and signal hyperintensity in T1-weighted MR imaging (T1WI) of carotid plaque according to stenosis severity and to estimate persistence of T1WI signal hyperintensity.

METHODS: A total of 222 patients (392 atherosclerotic carotid arteries) underwent plaque imaging using 3D inversion-recovery-based T1WI (magnetization-prepared rapid acquisition with gradient-echo [MPRAGE]). Carotid plaque with intensity on MPRAGE of >200% that of adjacent muscle was categorized as "high signal intensity" and correlated with ipsilateral ischemic events within the previous 6 months. A total of 58 arteries (35 patients) underwent repeat MR imaging a total of 70 times at a median interval of 279 days (range, 10–1037 days).

RESULTS: Ipsilateral ischemic events were more frequent in patients with MPRAGE high signals than in patients with low signals in the 0%–29%, 30%–69%, and 70%–99% stenosis groups: Relative risk (95% confidence interval) was 2.50 (0.96–6.51), 7.55 (1.84–31.04), and 1.98 (1.01–3.90), respectively. In the 70 cases of repeat MR imaging, 29 of 30 cases with high signals on the preceding MR imaging maintained high signals. Of the 58 arteries that underwent repeat MR imaging, 4 of 22 carotid arteries with high signals developed ipsilateral subsequent ischemic events within 1 year, whereas none with low signals developed subsequent events.

CONCLUSIONS: Carotid plaque signal hyperintensity on T1WI is strongly associated with previous ipsilateral ischemic events, persisting over a period of months, and may indicate risk of subsequent events. Larger clinical trials are warranted to clarify associations between signal hyperintensity and risk of subsequent cerebral ischemic events.

Atherosclerotic carotid plaque represents a major cause of cerebral ischemia.¹ Superiority of carotid endarterectomy to medical treatment has been confirmed for symptomatic carotid artery with severe stenosis (70%–99%) by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST), but ≥ 7 operations were performed to avoid 1 stroke.^{2,3} At the same time, symptomatic patients with 50%–69% stenosis have been shown to benefit from moderate reduction of stroke risk by surgery, whereas patients with <50% stenosis do not benefit from surgery.^{2,3} However, cerebral ischemic episodes are not restricted to severe stenosis of the carotid artery,^{2–4} and a substantial fraction of ischemic strokes in the territory of the carotid artery are unrelated to carotid stenosis.¹ Methods of noninvasively identifying "at risk" plaques are thus required.

Many studies have focused on MR imaging to characterize carotid plaques by using various imaging sequences. However, standardized sequence parameters and evaluation criteria to identify "at risk" plaques in MR imaging have not yet been established. Signal hyperintensity of carotid plaque in inversion recovery-based 3D T1-weighted imaging (alternatively known as magnetization-prepared rapid acquisition with gradient echo [MPRAGE])⁵ was associated with recent ischemic

events,^{6,7} and was related to complicated plaques (type VI as proposed by the American Heart Association).^{8,9}

We have performed carotid plaque imaging using MPRAGE since December 2001 for patients with suspected or confirmed carotid artery stenosis. The present study investigated associations between ischemic events and MPRAGE signal hyperintensity according to severity of stenosis in the carotid artery, and estimated persistence of MPRAGE signal hyperintensity as a potential risk factor for ischemic events.

Methods

Population

Since December 2001, MR imaging of the carotid artery has been performed for patients with suspected or confirmed atherosclerosis of the carotid artery after provision of oral informed consent on admission to the Departments of Neurology or Neurosurgery of our hospital. We reviewed the medical records of 222 consecutive patients who underwent MR imaging between December 2001 and June 2004. This study was performed in accordance with the ethics guidelines of our hospital. Of the 444 carotid arteries, 45 occluded arteries (at origin of the internal carotid artery, $n = 39$; common carotid artery, $n = 1$; top of the internal carotid artery or horizontal portion of the middle cerebral artery, $n = 5$) and 7 surgically treated carotid arteries (endarterectomy, $n = 5$; stent grafting, $n = 2$) were excluded from the study. A total of 392 carotid arteries from 222 patients were thus enrolled in this study.

Patient characteristics were recorded retrospectively by reviewing medical records. Ischemic events ipsilateral to the carotid artery within the previous 6 months were recorded, including cerebral infarction, transient ischemic attack, and retinal ischemia (amaurosis fugax and retinal artery occlusion). Emboligenic cardiac diseases (including persistent and paroxysmal atrial fibrillation, mitral valve stenosis, implantation of pros-

Received December 17, 2005; accepted after revision April 11, 2006.

From the Department of Radiology (N.Y., M.H., T.S., R.T., H.N.), Cerebrovascular Division, Department of Medicine (R.O., N.O., K.M., H.N.), and Department of Neurosurgery (K.I.), National Cardiovascular Center, Osaka, Japan.

This study was supported by funding from the Japanese Ministry of Health, Labour, and Welfare.

Address correspondence to Naoki Yamada, MD, Department of Radiology, National Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-0855 Japan; e-mail: naoyamad@hsp.ncvc.go.jp




Fig 1. Volume of plaque imaging.

A, Maximum intensity projection for contrast MRA of the cervical arteries. Volume of plaque imaging with MPRAGE is indicated between the 2 transverse bars.

B, Near-coronal multiplanar reconstruction of MPRAGE.

C, Source image of MPRAGE 3 mm cranial to the right carotid bifurcation shows relatively homogeneous signal intensity in the neck.

D, Zoomed source image of MPRAGE demonstrates dark lumen of the right internal carotid artery (ICA) and the external carotid artery (ECA). Circle indicates region of interest placed in the SCM.

E, Zoomed source image of TOF MRA at the same position demonstrates bright lumen of the carotid arteries. Plaque of the ICA (asterisk) demonstrates signal hyperintensity. SCM, sternocleidomastoid muscle.

thetic heart valves, dilated cardiomyopathy, endocarditis, and acute myocardial infarction within the previous 6 months) were also recorded. Recorded risk factors of atherosclerosis included hypertension, diabetes mellitus, hyperlipidemia, and cigarette smoking.

MR Imaging

MR imaging was performed using a Magnetom Sonata 1.5T system (Siemens, Erlangen, Germany) with standard neck array and spine array coils (Fig 1). Plaque imaging was performed using MPRAGE in transaxial section with null blood condition (effective inversion time, 660 ms; TR, 1500 ms) and the water excitation technique to suppress fat signals. TR was defined as the interval between successive inversion pulses. Other imaging variables were: TE, 5.0 ms; FOV, 180 × 180 mm; matrix, 256 × 204; section thickness, 1.25 mm; 56 partitions; covering 70 mm around the carotid bifurcation; data acquisition time, 5 minutes. Multislab 3D time-of-flight (TOF) MR angiography (MRA) was also performed to facilitate delineation of lumen shape and plaque morphology (TE, 4.4 ms; TR, 35 ms; same spatial resolution as MPRAGE). Contrast MRA was performed after MPRAGE and 3D TOF MRA using rapid infusion of 0.1 mmol/kg body-weight gadolinium-diethylene-triaminepentaacetic acid (Gd-DTPA) at a rate of 2.0–3.0 mL/s after a test bolus of 1 mL Gd-DTPA for timing evaluation at the same rate. Typical imaging variables comprised: TR, 3.2 ms; TE, 1.3 ms; section thickness, 1.0 mm; 64 partitions;

FOV, 360 × 200 mm; matrix, 512 × 208; data acquisition time, 14 seconds; near coronal section.

Follow-Up MR Imaging

Of the 222 patients, 28 patients underwent one repeat MR imaging and 7 patients underwent 2 repeat MRIs for follow-up of carotid atherosclerosis up to June 2005, depending on clinical demands. Among the 28 patients with one repeat MR imaging, 4 carotid arteries were excluded because of occlusion and 6 arteries were excluded as a result of surgical treatment before initial MR imaging ($n = 1$) and between initial and repeat MR imaging ($n = 5$). Among the 7 patients with 2 repeat MRIs, 2 arteries were excluded because of occlusion. MPRAGE signals from plaques were thus compared a total of 70 times in 58 arteries from 35 patients. For arteries that underwent 2 repeat MRIs, first repeat MR imaging was compared with initial MR imaging, and the second repeat MR imaging was compared with the first repeat MR imaging.

Evaluation of MR Imaging

Carotid stenosis was measured using contrast MRA according to the methods defined by the NASCET¹⁰ and categorized into 3 groups: mild or no stenosis (0%–29%), moderate stenosis (30%–69%), and severe stenosis (70%–99%). One observer evaluated signal intensity of plaques on MPRAGE relative to signal intensity in adjacent muscle




Fig 2. Examples of classic carotid plaques.

A, An example of low signal intensity plaque. Top and bottom rows show 3 corresponding sections with 2.5-mm intervals of TOF MRA and MPRAGE, respectively. A 76-year-old man has left carotid artery stenosis and no history of ipsilateral ischemic events. The carotid plaque (*arrows*) displays no signal hyperintensity relative to the adjacent muscle.

B, An example of high signal intensity plaque. Top and bottom rows show 3 corresponding sections with 2.5-mm intervals in initial and follow-up MR imaging. A 58-year-old man experienced cerebral infarction in the territory of the right middle cerebral artery 12 days before initial MR imaging, which reveals a right carotid plaque with heterogeneous MPRAGE signal hyperintensity (top row). At 4 months after initial MR imaging, the patient again developed cerebral infarction in the right middle cerebral artery territory. Follow-up MR imaging at 5 months after initial MR imaging (bottom row) shows mild increase of MPRAGE high signal intensity region.

(typically the sternocleidomastoid muscle) as measured by placing a round region of interest 5–8 mm in diameter on a standard console of the clinical MR system (Fig 1D). If the plaque displayed signal intensity $>200\%$ of muscle intensity at any place or section in the plaque, that plaque was categorized as “high signal intensity.” Otherwise, the plaque was categorized as “low signal intensity” (Fig 2).

For carotid plaque with high signal intensity, volume of the region with signal intensity $>200\%$ of the muscle intensity was calculated

using Dr. View/PRO version 5.2 software (Asahi Kasei Information Systems, Tokyo, Japan) on a stand-alone workstation.

Statistical Analysis

Two-tailed *t* tests or Mann-Whitney tests were used for comparison of means, 2-sided Fisher exact tests for comparison of proportions, paired *t* tests for comparison of paired variables, and χ^2 tests for linear trends of ischemic events according to stenosis severity. Associations

Table 1: Baseline characteristics of carotid arteries according to symptoms

	Symptomatic (n = 74)	Asymptomatic (n = 318)	P
Age (years)	69.9 ± 8.3*	70.0 ± 7.6	.8872
Female sex	14.9 (11/74)	17.3 (55/318)	.7309
AF and prosthetic heart valve	5.4 (4/74)	6.9 (22/318)	.7982
Hypertension	79.7 (59/74)	83.3 (265/318)	.4957
Diabetes mellitus	39.2 (29/74)	39.9 (127/318)	1.0000
Hyperlipidemia	62.2 (46/74)	56.0 (178/318)	.3630
Cigarette smoking	29.7 (22/74)	23.3 (74/318)	.2930

Note:—AF indicates atrial fibrillation. Values for age represent mean ± SD; other values represent percentage of carotid arteries, with raw numbers provided in parentheses.

between MPAGE signal intensity and ipsilateral ischemic events were analyzed by considering each artery independently. All analyses were performed using Prism version 4.0 software for Windows (GraphPad Software, San Diego, Calif).

To calculate interobserver variability in categorization of carotid plaque as high or low signal intensity, a second observer categorized carotid plaque signals for the first 100 arteries after completing consensus reading of the last 10 carotid plaques as training between first and second observers. For calculation of intraobserver variability, the first observer repeated categorization of plaque signals for the first 100 arteries at >1 month after first observation. All interpretations of MR imaging were performed in a blinded manner. Interobserver and intraobserver agreement was calculated using κ statistics.

Results

Association between Signal Hyperintensity and Previous Ischemic Events

A total of 74 carotid arteries were associated with ipsilateral ischemic events within the previous 6 months (cerebral infarctions, $n = 45$; transient ischemic attack, $n = 20$; retinal ischemia, $n = 9$). Patients displaying carotid arteries with and without ipsilateral ischemic events exhibited no significant differences in age, sex, hypertension, diabetes mellitus, hyperlipidemia, or cigarette smoking status. A total of 24 carotid arteries were present in patients with atrial fibrillation, whereas 2 carotid arteries were from a single patient with a prosthetic aortic valve (Table 1). No patients were diagnosed with mitral stenosis, dilated cardiomyopathy, endocarditis, or acute myocardial infarction.

MPAGE high signal intensity was assigned to 170 of 392 carotid plaques (Fig 2). The κ values for interobserver and intraobserver agreement were 0.729 and 0.792, respectively (good agreement). After excluding carotid arteries from patients with atrial fibrillation or prosthetic heart valves, a total of 370 carotid arteries were included in evaluation of association with previous ischemic events. Relative risks (95% confidence interval) of carotid arteries with MPAGE high signals compared with carotid arteries with MPAGE low signals for 0%–29%, 30%–69%, 70%–99% stenosis groups were 2.50 (0.96–6.51), 7.55 (1.84–31.04), and 1.98 (1.01–3.90), respectively (Table 2). In addition, risk of high signal intensity carotid arteries with 0%–29% and 30%–69% stenoses resembled risk of low signal intensity carotid arteries with 70%–99% stenosis: relative risks (95% confidence intervals [CI]) were 0.87 (0.34–2.24) and 1.34 (0.65–2.78), respectively. Frequency of ischemic events in MPAGE high signal intensity plaques increased with stenosis severity ($P = .0133$). Median interval between MR imaging and previous ischemic

events for MPAGE high and low signal intensity groups was 20 days (range, 0–180 days) and 51 days (range, 6–179 days), respectively. Mann-Whitney tests revealed no significant differences between the 2 intervals ($P = .0854$).

In MPAGE high signal intensity plaques, volume of the high signal intensity region was larger in symptomatic plaques than in asymptomatic plaques. Mean (\pm SD) volume for 0%–29%, 30%–69%, and 70%–99% stenosis groups in symptomatic plaques was 249 ± 301 , 186 ± 327 , and 166 ± 331 mm³, respectively—larger than in asymptomatic plaques at 48 ± 72 , 123 ± 169 , and 115 ± 200 mm³, respectively. Mann-Whitney tests revealed a significant difference for 0%–29% stenosis ($P = .0247$) but not for 30%–69% ($P = .5102$) or 70%–99% stenosis ($P = .3177$).

Follow-Up MR Imaging

A total of 70 comparisons in 58 arteries were performed between successive MRIs at a median interval of 279 days (range, 10–1037 days). Initial status of high or low signal intensity was maintained on repeat MR imaging for most comparisons; only 4 of 40 low signal intensity carotid arteries changed to high signal intensity, and only 1 of 30 high signal intensity carotid arteries changed to low signal intensity (Table 3). Volume of the region with signal intensity >200% of muscle intensity tended to be similar between successive MRIs ($P = .690$) (Fig 3). Mean stenosis did not change significantly in the 70 comparisons, at $44.2 \pm 30.0\%$ for the preceding MR imaging and $45.0 \pm 30.2\%$ for follow-up MR imaging ($P = .487$).

For investigation of subsequent events, 6 arteries from patients with atrial fibrillation and 2 arteries with ipsilateral middle cerebral artery occlusion at the horizontal portion were excluded from the 58 arteries. Among the remaining 50 carotid arteries, 4 of 22 carotid arteries with high signals displayed subsequent events, compared with 0 of 28 arteries with low signals ($P = .0473$) (Table 4). Repeat MR imaging of the 4 carotid arteries with subsequent events was performed at 9, 16, 16, and 27 days after subsequent events. Volume of the 4 arteries did not reveal any specific features compared with the other arteries (Fig 3).

Discussion

More ischemic events occurred in patients with high signals on MPAGE than in those who showed low signals in each of the subgroups of patients with mild, moderate, and severe stenosis. Volume of high signal intensity was significantly larger in symptomatic plaque than in asymptomatic plaque for patients with mild stenosis. We also demonstrated in a subgroup that underwent multiple MR imaging that hyperintensity was maintained over a period of months, and MPAGE high signals may offer an indicator of risk for subsequent events.

MPAGE is a T1WI and displays intraplaque components that have short T1 as high signal intensity. Mechanisms of the short T1, however, are complex. Many previous studies have shown that lipid-rich necrotic cores display signal hyperintensity on T1WI.^{11–14} Other studies have shown that intraplaque hemorrhage or thrombus exhibit high signal intensity on T1WI.^{9,14–16} Although methemoglobin is considered to be a cause of high signal intensity, the duration of methemoglobin in carotid plaques remains unclear. Lipid signals are very weak in advanced plaques.¹¹ Signal hyperintensity in this study was not attributable to lipids, as fat-suppression technique was

Table 2: Risk of ipsilateral ischemia according to MPRAGE signal intensity and stenosis after excluding patients with atrial fibrillation and prosthetic heart valves

Stenosis	0%–29% (n = 152)			30%–69% (n = 114)			70%–99% (n = 100)			Total (n = 366)		
	S	A	F (%)	S	A	F (%)	S	A	F (%)	S	A	F (%)
MPRAGE												
High signal intensity	6	26	18.8	18	44	29.0	27	36	42.9	51	106	32.5
Low signal intensity	9	111	7.5	2	50	3.8	8	29	21.6	19	190	9.1
P		0.0889			0.0004			0.0498			<0.0001	
Relative risk (95% CI)	2.500 (0.9603–6.508)			7.548 (1.836–31.041)			1.982 (1.008–3.900)			3.573 (2.201–5.801)		

Note:—MPRAGE indicates magnetization-prepared rapid acquisition with gradient echo; S, symptomatic within previous 6 months; A, asymptomatic within previous 6 months; F, frequency of carotid arteries in patients with ipsilateral symptom; CI, confidence interval. P values were calculated using the Fisher exact test between MPRAGE high and low groups for symptoms (S) in each stenosis group. Relative risk of ischemic events was calculated for MPRAGE high carotid arteries compared with low carotid arteries in each stenosis group.

Table 3: Number of carotid arteries displaying MPRAGE high and low signal intensity according to interval between repeat and the preceding MRI, and signal intensity change on repeat MRI

Interval	Number on Preceding MRI		Number Associated with Signal Intensity Change on Repeat MRI	
	High	Low	High to Low	Low to High
<90 days	5	9	1	0
90–179 days	8	7	0	1
180–364 days	9	8	0	0
≥ 365 days	8	16	0	3
Total	30	40	1	4




Fig 3. Comparison of high signal intensity volume between successive MR imaging. Comparison was done 34 times between 2 successive MR imagings with high signal intensity in both or either of the 2 MR images. Median interval was 279 days (range, 10–1037 days). High signal intensity volume (mean \pm SD) was 149 ± 182 mm³ at the initial MR imaging and 144 ± 217 mm³ at the repeat MR imaging. Paired *t* test displayed no significant change (*P* = .690). Broken lines indicate 4 carotid arteries associated with subsequent events within 1 year after initial MR imaging.

used. Protein-rich viscous tissue can form another cause of signal hyperintensity.^{17–19} The actual cause of T1WI signal hyperintensity should thus be investigated further.

In the follow-up study, signal hyperintensity was repeatedly observed (Table 3), and high signal intensity volume did not change significantly. Repeat MR imaging of 4 carotid arteries with subsequent events that was performed 9–27 days after these events exhibited no specific change in volume compared with the other arteries (Fig 3). These results may be attributable to continuous or recurrent intraplaque hemorrhage. However, we cannot conclude that signal hyperintensity is due to recent hemorrhage

in this study. Erythrocyte membranes and iron have been shown to be present within the necrotic cores of human atherosclerotic coronary plaques even in the absence of recent hemorrhage, and intraplaque hemorrhage is related to progression and instability of such lesions.²⁰ If this is the case in carotid plaque, as in coronary plaque, the necrotic core of a carotid plaque can be at least partially formed by intraplaque hemorrhage, and thus no clear border would exist between intraplaque hemorrhage and necrotic core.

Size and location of high signals may be important for vulnerability. In the coronary artery, “at risk” plaques can be morphologically characterized by a large lipid-rich core and thin fibrous cap.^{8,21} In the case of the carotid artery, however, numerous authors have stressed the importance of intraplaque hemorrhage.^{22,23} Conversely, other authors have reported no significant differences in frequency of hemorrhage between symptomatic and asymptomatic patients.^{24–26} The real causes of carotid plaque vulnerability thus remain controversial. Volume of the high signal intensity region was significantly larger in symptomatic carotid plaque than in asymptomatic plaque for the 0%–29% stenosis category, but not for the 30%–69% or 70%–99% categories. Carotid plaques with subsequent events did not display extremely large volumes for high signal intensity regions (Fig 3). Assessment of fibrous cap thickness and integrity is also important when evaluating plaque vulnerability and has been achieved using T2-weighted imaging and TOF MRA.^{11,27,28} Some authors have reported higher percentages of symptomatic patients for ruptured caps (70%) compared with thick caps (9%) using multicontrast MR imaging.²⁹ Plaque ulceration may be related to stroke risk.^{30,31} Better prediction of vulnerability may be achieved by combining MPRAGE with these techniques.

This study was performed using a commercially available clinical machine and standard neck- and spine-array coils without additional hardware. Image acquisition time was short (5 minutes for MPRAGE). MPRAGE with fat suppression and null blood condition suppresses background signals and highlights signal hyperintense tissues with short T1, so image interpretation is relatively simple.^{7,9,32} Although motion artifacts were present to various degrees, predominantly attributable to respiration and swallowing, these were insufficient to result in the exclusion of any patients from the present study. 3D data acquisition is essential for visualizing the entirety of irregularly shaped plaques.

This study examined suspected and confirmed atherosclerotic carotid stenosis that may be related to cerebral ischemia depending upon clinical demands. Some biases in the study population

Table 4: Subsequent ipsilateral events according to stenosis severity and MPRAGE signals: results of 1 year follow-up after initial MRI

Stenosis	Number at Initial MRI	Subsequent Events		
		Ischemic Events	Surgical Treatment	Censored
Number of low signal intensity carotid arteries				
0%–29% Stenosis	9	0	0	1
30%–69% Stenosis	13	0	0	0
70%–99% Stenosis	6	0	3	0
Total	28	0	3	1
Number of high signal intensity carotid arteries				
0%–29% Stenosis	6	0	0	0
30%–69% Stenosis	7	1	1	0
70%–99% Stenosis	9	3	5	0
Total	22	4	6	0

Note:—MPRAGE indicates magnetization-prepared rapid acquisition with gradient echo. Ischemic events include ischemic stroke and transient ischemic attack. Surgical treatment includes carotid endarterectomy and endovascular stenting.

may thus be present. Reasons for MR imaging of the carotid artery varied, including screening of cervical artery stenosis, suspicion of complicated plaque on ultrasonography, inconclusive ultrasonography results due to calcification and high position of stenosis, refusal of conventional angiography by patients, and preoperative evaluation of carotid artery stenosis. Potential embolic sources, such as complicated plaque in the aortic arch and persistent foramen ovale, were not surveyed.

Conclusion

We conclude that carotid plaque hyperintensity on MPRAGE, a heavy 3D T1WI technique, is associated with previous cerebral ischemic events. MPRAGE hyperintense signals persist over a period of months, and may represent a potential indicator of risk for subsequent cerebral ischemia. Longitudinal studies with large subject populations are required to clarify whether MPRAGE hyperintense signals indicate risk of subsequent cerebral ischemic events.

Acknowledgments

We thank Teruo Noguchi from the National Cardiovascular Center for his helpful comments and discussions.

References

- Barnett HJ, Gunton RW, Eliasziw M, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. *JAMA* 2000;283:1429–36
- Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med* 1998;339:1415–25
- Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results of the European Carotid Surgery Trial. *Stroke* 2003;34:514–23
- Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. *Stroke* 2000;31:774–81
- Mugler JP 3rd, Brookeman JR. Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MPRAGE). *Magn Reson Med* 1990;15:152–57
- Moody AR, Alder S, Lennox G, et al. Direct magnetic resonance imaging of carotid artery thrombus in acute stroke. *Lancet* 1999;353:122–23
- Murphy RE, Moody AR, Morgan PS, et al. Prevalence of complicated carotid atheroma as detected by magnetic resonance direct thrombus imaging in patients with suspected carotid artery stenosis and previous acute cerebral ischemia. *Circulation* 2003;107:3053–58
- Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol* 1995;15:1512–31
- Moody AR, Murphy RE, Morgan PS, et al. Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. *Circulation* 2003;107:3047–52
- Anonymous. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. *Stroke* 1991;22:711–20
- Toussaint JF, Southern JF, Fuster V, et al. T2-weighted contrast for NMR characterization of human atherosclerosis. *Arterioscler Thromb Vasc Biol* 1995;15:1533–42
- Rogers WJ, Prichard JW, Hu YL, et al. Characterization of signal properties in atherosclerotic plaque components by intravascular MRI. *Arterioscler Thromb Vasc Biol* 2000;20:1824–30
- Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. *J Magn Reson Imaging* 2002;15:62–67
- Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplate hemorrhage in advanced human carotid plaques. *Circulation* 2001;104:2051–56
- Cappendijk VC, Cleutjens KB, Heeneman S, et al. In vivo detection of hemorrhage in human atherosclerotic plaques with magnetic resonance imaging. *J Magn Reson Imaging* 2004;20:105–10
- Cappendijk VC, Cleutjens KB, Kessels AG, et al. Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience. *Radiology* 2005;234:487–92
- Hayashi Y, Tachibana O, Muramatsu N, et al. Rathke cleft cyst: MR and biomedical analysis of cyst content. *J Comput Assist Tomogr* 1999;23:34–38
- Ahmadi J, Destian S, Apuzzo ML, et al. Cystic fluid in craniopharyngiomas: MR imaging and quantitative analysis. *Radiology* 1992;182:783–85
- Kucharczyk W, Macdonald PM, Stanisz GJ, et al. Relaxivity and magnetization transfer of white matter lipids at MR imaging: importance of cerebrospines and pH. *Radiology* 1994;192:521–29
- Kolodgie FD, Gold HK, Burke AP, et al. Intraplate hemorrhage and progression of coronary atheroma. *N Engl J Med* 2003;349:2316–25
- Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. *Nat Med* 2002;8:1257–62
- Lusby RJ, Ferrell LD, Ehrenfeld WK, et al. Carotid plaque hemorrhage. Its role in production of cerebral ischemia. *Arch Surg* 1982;117:1479–88
- Imparato AM, Riles TS, Mintzer R, et al. The importance of hemorrhage in the relationship between gross morphologic characteristics and cerebral symptoms in 376 carotid artery plaques. *Ann Surg* 1983;197:195–203
- Bassiouny HS, Davis H, Massawa N, et al. Critical carotid stenoses: morphologic and chemical similarity between symptomatic and asymptomatic plaques. *J Vasc Surg* 1989;9:202–12
- Hatsukami TS, Ferguson MS, Beach KW, et al. Carotid plaque morphology and clinical events. *Stroke* 1997;28:95–100
- Svindland A, Torvik A. Atherosclerotic carotid disease in asymptomatic individuals: An histological study of 53 cases. *Acta Neurol Scand* 1988;78:506–17
- Toussaint JF, LaMuraglia GM, Southern JF, et al. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. *Circulation* 1996;94:932–38
- Hatsukami TS, Ross R, Polissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. *Circulation* 2000;102:959–64
- Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. *Circulation* 2002;105:181–85
- Eliasziw M, Streifler JY, Fox AJ, et al. Significance of plaque ulceration in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial. *Stroke* 1994;25:304–08
- Rothwell PM, Gibson R, Warlow CP. Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis. On behalf of the European Carotid Surgery Trialists' Collaborative Group. *Stroke* 2000;31:615–21
- Moody AR, Pollock JG, O'Connor AR, et al. Lower-limb deep venous thrombosis: direct MR imaging of the thrombus. *Radiology* 1998;209:349–55

Revascularization of Malignant Coronary Instant Restenosis Resulting From Takayasu's Arteritis Using Sirolimus-Eluting Stents

Hidetsugu SAKAI,¹ MD, Naotsugu OYAMA,² MD, Noriaki KISHIMOTO,¹ MD, Masashige TAKAHASHI,¹ MD, Kazushi URASAWA,³ MD, and Hiroyuki TSUTSUI,³ MD

SUMMARY

A 37 year-old female who had suffered from arteritis for 20 years underwent a Bentall operation. Since severe stenosis was observed in her left main coronary artery (LMCA) the following year, a minimally invasive direct coronary artery bypass (MIDCAB) operation was performed. Unfortunately, she again complained of angina about 6 months after the second surgery and coronary angiography (CAG) revealed that her left internal thoracic artery graft was totally occluded. Although a 4.0 × 15 mm S670 stent was placed in her LMCA, the LMCA restenosed every 3 months and she underwent reintervention 8 times. We placed 2 sirolimus-eluting stents for treating the LMCA using the culottes stenting technique. CAG 6 months after the index procedure showed no stenosis at her LMCA. Sirolimus-eluting stents were effective for treating stenosis resulting from arteritis as well as that caused by atherosclerosis. (Int Heart J 2006; 47: 795-801)

Key words: Arteritis, Restenosis, Sirolimus, Stent

SIROLIMUS has an antiproliferative effect against vascular smooth muscle cells, and many investigators have already reported that sirolimus-eluting stent (SES) placement is more effective for treating atherosclerotic coronary artery narrowing than conventional bare metal stent placement. However, there have been very few reports on whether SES placement is effective against coronary artery stenosis caused by arteritis.

We report herein the case of a young female patient suffering from arteritis in whom malignant instant restenosis was treated successfully with an SES. This is a rare case showing the efficacy of SES for treating LMCA stenosis caused by arteritis.

From the ¹ Division of Cardiology, Kushiro Rosai Hospital, Hokkaido, Japan, ² Vascular Medicine Research, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA and ³ Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.

Address for correspondence: Hidetsugu Sakai, MD, Division of Cardiology, Kushiro Rosai Hospital, 13-23, Nakazono-cho, Kushiro, Hokkaido 085-8533, Japan.

Received for publication March 23, 2006.

Revised and accepted June 29, 2006.

CASE REPORT

A 37 year-old female was referred to our institution by another hospital in order to treat her transluminally. She had suffered from Takayasu's arteritis for 20 years, and received an aortic valve replacement (AVR) using a bioprosthetic valve when she was 27 years old. In the following year, complete atrioventricular block appeared, and she underwent permanent pacemaker implantation. Since an aortic root aneurysm appeared when she was 34 years old, a Bentall operation and reAVR were performed. That is, her aortic valve was exchanged to a mechanical prosthetic valve and her LMCA was reconstructed using the Piehler technique.¹⁾ Another year later, she complained of chest pain and coronary angiography (CAG) revealed that her native LMCA was severely stenosed. Her left internal thoracic artery (LITA) was grafted onto her left anterior descending coronary artery (LAD) with a minimally invasive direct coronary artery bypass (MID-CAB) operation. She again complained of angina about 6 months after the MID-CAB operation and CAG revealed that her LITA graft was totally occluded (Figure 1). A 4.0 × 15 mm S670 stent (Medtronic AVE) was placed onto the




Figure 1. Angiography of left internal thoracic artery.
* : Anastomosis of left internal thoracic artery graft was occluded.
** : Implanted permanent pacemaker
*** : Replaced prosthetic aortic valve

stenosed LMCA and it was adequately postdilated using a 6.0×20 mm Maverick-XL balloon catheter (SciMed, Boston Scientific). After this stenting, however, her stented LMCA restenosed about every 3 months, and conventional or cutting balloon angioplasty was performed to compress the intrastent neointima to the exterior of the stent struts on all such occasions. She underwent a total of 8 transcatheter target lesion revascularizations.




Figure 2. Preprocedural spider view of left coronary angiography: left main coronary artery (LMCA) was severely stenosed.




Figure 3. Postprocedural spider view of left coronary angiography: LMCA bifurcation lesion was dilated with the culottes stenting technique using 2 Cypher stents.



Figure 4. Chronic phase angiography of left coronary artery: No restenosis was observed.

The Cypher stent (Johnson & Johnson, Cordis), approved in Japan in August 2004, was used to treat her. When she was admitted to our hospital, she again complained of chest pain on effort and CAG revealed severe narrowing had reappeared at her LMCA (Figure 2). We electively planned to dilate her LMCA lesion with the culottes stenting technique by using 2 Cypher stents and electively treated her 3 days later.²⁾ After the LMCA was engaged with a 7Fr JL4.0ST Brite-tip guiding catheter (Johnson & Johnson, Cordis) via her right femoral artery, a 0.014" Runthrough-NS floppy guidewire (Terumo) and a 0.014" Hi-torque balance middleweight guidewire (Guidant) easily crossed the lesion toward her LAD and left circumflex coronary artery (LCX), respectively. Preprocedural intravascular ultrasonography (IVUS) with a 2.5Fr Atlantis-SR Pro imaging catheter (SciMed, Boston Scientific) was performed. IVUS images revealed that the previously implanted S670 stent was fully expanded and the stent diameter was about 5.8 mm, and that the intrastent lumen was occupied by a massive amount of hyperplastic neointima. Without predilatation, a 3.5 × 23 mm Cypher stent was delivered and placed onto the native LMCA extending over her proximal LCX. The Hi-torque balance middleweight guidewire inserted into her LCX was partially removed and advanced to her LAD through the stent cell. The Runthrough-NS floppy guidewire was completely removed and advanced to her LCX. We advanced a 3.0 × 20 mm Maverick-2 balloon catheter (SciMed, Boston Scientific) along the Hi-torque balance middleweight guidewire, positioned it across the stent cell, and dilated it to expand the cell. Next, we delivered a 3.5 × 18 mm Cypher stent across the expanded stent cell toward the LAD and placed it onto her native LMCA extending over the proximal LAD. Again, the Hi-torque balance middleweight guidewire inserted into the LAD was partially removed and advanced to the LCX through the stent cell. The Runthrough-NS floppy guidewire was completely removed and advanced to her LAD. Then, we again advanced the previously used 3.0 × 20 mm Maverick-2 balloon catheter toward the LCX, positioned it across the stent cell, and dilated it. In order to perform adequate postdilatation with an alternative kissing balloon technique, we advanced a 5.0 × 20 mm Maverick-XL balloon catheter and dilated it within her LMCA, proximal LAD, and proximal LCX. Finally, full expansion of the 2 Cypher stents was confirmed with both CAG and IVUS to complete the procedure (Figure 3).

She was discharged the day following the procedure and has not complained of any angina since. Another CAG performed 6 months after the procedure showed no restenosis of the stented segments (Figure 4).

DISCUSSION

Takayasu's arteritis or pulseless disease is a chronic and progressive inflam-

matory vasculitis that usually occurs in young women and is characterized by stenosis or obliteration of large and medium sized arteries, and its early morbidity and/or mortality results from ischemia of vital organs.^{3,4)} Coronary artery disease is not a rare involvement of arteritis and its incidence has been reported to be 9-10%,^{4,5)} however, the ratio is usually derived from autopsy studies. The actual clinical manifestation appears to be relatively unappreciated because coronary artery disease is not evident in most cases until the occurrence of angina or myocardial infarction.^{5,6)} Matsubara and colleagues classified coronary lesions involved in arteritis into 3 types on the basis of pathological features and reported that stenosis or occlusion of the ostia and proximal segments of the coronary tree were most commonly seen.⁵⁾ In those diseased vessels, the extension of the inflammatory processes of the intimal proliferation and contraction of the fibrotic media and adventitia from the ascending aorta cause luminal narrowing.⁵⁾ In our patient, a significant narrowing occurred at her LMCA even after it was separated from her native ascending aorta due to the Bentall operation. The aforementioned classification of Matsubara, *et al* includes focal coronary arteritis, so-called skip lesions, therefore, her LMCA lesion possibly corresponded not to typical extending disease from the aorta but to the skip lesion.⁵⁾

There have been few reports regarding transcatheter treatment of coronary artery disease resulting from arteritis. The most likely reason is that lesion location is usually ostial or proximal coronary segments like the LMCA, which are unsuitable for percutaneous angioplasty. Moreover, blood access sites would be limited in many cases if morbid changes occur at main branches of the aorta such as the iliac, subclavian, and innominate arteries. Aortic disease itself, like aneurysm, might disturb intraaortic catheter manipulation.

We encountered a young patient enduring considerable suffering who received LMCA stenting after a failed MIDCAB operation and many transcatheter revascularizations. We successfully treated her using sirolimus-eluting stents with the culottes stenting technique and obtained satisfactory chronic phase patency of the treated vessels. During the procedure, IVUS revealed that the stent deployed at her LMCA was fully expanded. That is, the stent prevented vessel contraction of the fibrotic media and adventitia. However, adequate steroid therapy unfortunately could not prevent intimal proliferation, which is one of the main causes of coronary narrowing resulting from arteritis.

Chronic phase restenosis is one of the weak points of percutaneous coronary intervention therapy. Every improvement in the interventional procedure and oral systemic pharmacological intervention have failed to achieve satisfactory results regarding the chronic phase patency of treated vessels after transcatheter coronary intervention. Recently, local drug delivery using drug-eluting stents has been proven to have encouraging results with respect to the prevention of instant

restenosis. Many investigators have already reported that SES, which is one of the better known drug-eluting coronary stents, is quite effective for not only the treatment of simple coronary narrowing like Stress/Benestent lesions but also that of complex stenosis like LMCA-stenosis, bifurcation lesions, and diffuse long stenosis.⁷⁻¹⁵⁾ However, all of these lesions treated in previous clinical studies were caused by atherosclerosis.

Takayasu's arteritis often afflicts young Asian women, and the number of white patients afflicted is small.¹⁶⁾ This most likely accounts for the reason there have been few reports on whether SES placement is effective against coronary artery stenosis caused by arteritis. As discussed by Furukawa and colleagues, the pathological features of diseased vessels in Takayasu's arteritis is predominant infiltration of various kinds of immunocytes.¹⁷⁾ It is well known that sirolimus has potent immunosuppressive effects although it was originally developed as an antibiotic agent. Therefore, this pharmacological function of SES brings excellent short- and mid-term vessel patency after its placement, however, it is unknown whether this good mid-term finding can extend to a long-term effect after sirolimus coated on the stent struts is completely diffused in the same way as its placement to treat simple atherosclerosis.

We have described a case of LMCA disease resulting from arteritis, and SES was quite efficacious against the intimal hyperplasia. However, long-lasting observation is essential since most patients with Takayasu's arteritis are young and the arteritis is a progressive disease in nature. We are able to conclude, however, that SES placement is a potent candidate for revascularization whose aim is to free arteritis patients from myocardial ischemia.

REFERENCES

1. Piehler JM, Pluth JR. Replacement of the ascending aorta and aortic valve with a composite graft in patients with nondisplaced coronary ostia. *Ann Thorac Surg* 1982; 33: 406-9.
2. Lefevre T, Louvard Y, Morice MC, *et al.* Stenting of bifurcation lesions: classification, treatments, and results. *Catheter Cardiovasc Interv* 2000; 49: 274-83.
3. Hodgins GW, Dutton JW. Transluminal dilatation for Takayasu's arteritis. *Can J Surg* 1984; 27: 355-7.
4. Suzuki H, Daiba H, Tanaka M, *et al.* Giant aneurysm of the left main coronary artery in Takayasu aortitis. *Heart* 1999; 81: 214-7.
5. Matsubara O, Kuwata T, Nemoto T, Kasuga T, Numano F. Coronary artery lesions in Takayasu arteritis: pathological considerations. *Heart Vessels Suppl* 1992; 7: 26-31.
6. Thomas D, Dubourg O, Bletry O, *et al.* Coronary involvement in Takayasu's disease. Apropos of 3 cases, of which 2 were surgically treated, and review of the literature. *Arch Mal Coeur Vaiss* 1984; 77: 386-96. (Review)(French)
7. Morice MC, Serruys PW, Sousa JE, *et al.* Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with *de Novo* Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002; 346: 1773-80.

8. Moses JW, Leon MB, Popma JJ, *et al.* Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003; 349: 1315-23.
9. Schofer J, Schluter M, Gershlick AH, *et al.* Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). *Lancet* 2003; 362: 1093-9.
10. Arampatzis CA, Lemos PA, Hoye A, *et al.* Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. *Catheter Cardiovasc Interv* 2004; 62: 292-6; discussion 297.
11. Colombo A, Moses JW, Morice MC, *et al.* Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation* 2004; 109: 1244-9.
12. Degertekin M, Arampatzis CA, Lemos PA, *et al.* Very long sirolimus-eluting stent implantation for *de novo* coronary lesions. *Am J Cardiol* 2004; 93: 826-9.
13. Schampaert E, Cohen EA, Schluter M, *et al.* The Canadian study of the sirolimus-eluting stent in the treatment of patients with long *de novo* lesions in small native coronary arteries (C-SIRIUS). *J Am Coll Cardiol* 2004; 43: 1110-5.
14. Chieffo A, Stankovic G, Bonizzoni E, *et al.* Early and mid-term results of drug-eluting stent implantation in unprotected left main. *Circulation* 2005; 111: 791-5.
15. Park SJ, Kim YH, Lee BK, *et al.* Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. *J Am Coll Cardiol* 2005; 45: 351-6.
16. Amano J, Suzuki A. Coronary artery involvement in Takayasu's arteritis. Collective review and guideline for surgical treatment. *J Thorac Cardiovasc Surg* 1991; 102: 554-60. (Review)
17. Furukawa Y, Tamura T, Toma M, *et al.* Sirolimus-eluting stent for in-stent restenosis of left main coronary artery in Takayasu arteritis. *Circ J* 2005; 69: 752-5.